These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37981560)

  • 21. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.
    Dombret H; Thomas X; Chevallier P; Nivot E; Reitan J; Barber B; Barlev A; Mohty M
    J Med Econ; 2016 Nov; 19(11):1034-1039. PubMed ID: 27207188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.
    MacEwan JP; Batt K; Yin W; Peneva D; Sison S; Vine S; Chen C
    Leuk Lymphoma; 2018 Apr; 59(4):941-949. PubMed ID: 28805105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
    Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
    Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
    [No Abstract]   [Full Text] [Related]  

  • 28. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
    Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
    Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States.
    Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Cong Z
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):573-580. PubMed ID: 29923428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
    Vanderpoel J; Emond B; Ghelerter I; Milbers K; Lafeuille MH; Lefebvre P; Ellis LA
    Pharmacoecon Open; 2023 Jul; 7(4):617-626. PubMed ID: 37074589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 33. Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.
    Pandya BJ; Chen CC; McGuiness CB; Sullivan L; Feng Q; Walsh E; Borate U
    Expert Rev Hematol; 2022 Sep; 15(9):857-866. PubMed ID: 35924860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany.
    Steinmetz TH; Singh M; Lebioda A; Fink L; Schoehl M; Rieth A; Gonzalez-McQuire S; Engelhardt M
    J Med Econ; 2021; 24(1):114-122. PubMed ID: 33390079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
    Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
    Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
    J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.